問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
CHANGHUA CHRISTIAN HOSPITAL
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2022-02-16 - 2026-12-31
Condition/Disease
Test Drug
Participate Sites9Sites
Recruiting9Sites
2024-08-26 - 2026-07-23
Participate Sites7Sites
Recruiting7Sites
2021-05-31 - 2027-12-31
Participate Sites6Sites
Recruiting5Sites
Terminated1Sites
2019-01-01 - 2028-12-31
2016-11-01 - 2024-12-31
Participate Sites1Sites
Recruiting1Sites
2023-12-01 - 2027-12-31
-
2021-11-01 - 2031-12-31
Participate Sites5Sites
2021-02-08 - 2023-07-20
ER (+), HER2 (-) breast cancer
SAR439859
Not yet recruiting1Sites
Recruiting6Sites
2020-06-30 - 2024-10-11
To verify the efficacy of Toripalimab combined with Bevacizumab as the firstline therapy for advanced hepatocellular carcinoma (HCC).
Toripalimab (JS001)
Participate Sites3Sites
Recruiting3Sites
2023-06-30 - 2024-01-31
全部
